Cholesterol and the Biology of Alzheimer's Disease
Open Access
- 1 January 2004
- journal article
- review article
- Published by Elsevier BV in Neuron
- Vol. 41 (1), 7-10
- https://doi.org/10.1016/s0896-6273(03)00840-7
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor proteinProceedings of the National Academy of Sciences of the United States of America, 2003
- Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances β-Amyloid ProductionIn VivoJournal of Neuroscience, 2003
- Apolipoprotein E ϵ4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer DiseaseAnnals of Internal Medicine, 2002
- Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's diseaseNeuroscience Letters, 2002
- Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide.International Journal of Neuropsychopharmacology, 2001
- Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10Proceedings of the National Academy of Sciences of the United States of America, 2001
- Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivoProceedings of the National Academy of Sciences of the United States of America, 2001
- Differential effects of lovastatin treatment on brain cholesterol levels in normal and ApoE-deficient miceNeuroReport, 2001
- Statins and the risk of dementiaThe Lancet, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.JCI Insight, 1998